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Abstract
Background: The study of the endotoxin tolerance phenomenon in light of the recently defined roles of mast
cells and toll-like receptors as essential components of the innate immune response and as orchestrators of
acquired immunity may reveal potentially useful mechanisms of immunomodulation of infectious and allergic
inflammatory responses, such as sepsis or asthma. Here we evaluated the phenomenon of direct tolerance of
endotoxins, as well as the induction of cross-tolerance and synergism by stimulation with toll-like receptor-2 (TLR2)
and FcεR1 agonists, in murine mast cells prestimulated with lipopolysaccharide (LPS). Additionally, we evaluated
some stimulatory and inhibitory signaling molecules potentially involved in these phenomena.
Methods: MC/9 cells and primary bone marrow-derived mast cells obtained from C57BL/6 and TLR4
-/- knock-out
mice were sensitized to DNP-HSA (antigen) by incubation with DNP-IgE and were prestimulated with LPS for 18 hr
prior to stimulation. Cultures were stimulated with LPS or Pam3Cys-Ser-(Lys)4 3HCl (P3C), a TLR2 agonist,
individually or in combination with antigen. The production of IL-6 and TNFa, the phosphorylation of NFB and
p38 MAPK, and the expression of TLR4 and SOCS-1 and -3 were analyzed.
Results: We found that production of TNFa and IL-6 in murine mast cells that have been pretreated with LPS and
challenged with TLR4 (LPS) or -2 (P3C) agonists was reduced, phenomena described as endotoxin tolerance (LPS)
and cross-tolerance (P3C), respectively. The expression of TLR4 was not affected by LPS pretreatment. Our results
show that the FcεR1 agonist DNP-HSA (antigen) interacts synergistically with LPS or P3C to markedly enhance
production of cytokines (TNFa and IL-6). This synergistic effect with LPS and P3C was also attenuated by LPS
pretreatment and was mediated by TLR4. These results may be attributed to the reduction in phosphorylation of
the mitogen-activated protein kinase (MAPK), p38, and the transcription factor NFB, as well as to an increase in
the expression of the suppressors of cytokine signaling (SOCS)-1 and -3 proteins in LPS-pretreated mast cells.
Conclusions: These findings can be explored with respect to the modulation of inflammatory responses associated
with infectious and allergic processes in future studies.
Background
Currently, treatment of sepsis is ineffective and few
therapeutic innovations have been developed to improve
it [1,2]. Since 1972, stemming from the quasi-intuitive
ideas of Thomas Lewis [3], the concept that our
immune response to infection is the sustaining founda-
tion for sepsis has been widely accepted. An increased
understanding of sepsis pathophysiology has provided
stronger support for this hypothesis [4]. During the sec-
ond half of the 1990 s, two coinciding facts led to new
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discovery of toll-like receptors (TLR) [5,6] initiated our
present comprehension of how the host recognizes
pathogen molecular patterns, how the innate response is
initiated, and how the acquired immune response is
organized [7]. Second, in 1996, Bernd Echtenacher et al.
determined the essential role of mast cells in the innate
immune response using a model of peritoneal sepsis in
mast cell-deficient mice [8]. Additional work from other
groups (reviewed in 9) elevated these cells, previously
considered mere effectors, to the category of sentinels of
the innate immune system and organizers of the adap-
tive immune response. In fact, their permanent location
in sites likely to suffer invasion by pathogens - skin,
paranasal sinuses, lungs, and intestinal mucosa - places
them in a privileged position in terms of detection and
subsequent organization of the immune response. Innu-
merable possibilities for modulation of the inflammatory
response appeared after a better understanding of the
role played by TLRs was gained, having as targets their
stimulatory and inhibitory signaling pathways [10]. The
accumulation of evidence defining mast cells as funda-
mental in the immune response to sepsis [11-13] opens
up new perspectives on the mechanisms of immunomo-
dulation by this type of cell [14].
Interaction between responses to infectious and aller-
gic stimuli has been suggested on several levels, raising
the possibility of a common pathway. Genetics-based
studies have revealed the association of polymorphisms
in the myosin light chain kinase (MYLK) gene with
increased risk of sepsis and acute pulmonary injury.
This same gene is involved in other inflammatory
pathologies, including bronchial asthma [15]. Epidemio-
logical data have demonstrated the effect of exposure to
TLR agonists on the incidence of allergic phenomena
[16]. Experimental studies in human mast cell cultures
have shown an interaction between FcεR1 receptors and
TLR2 [17]. In bone marrow derived-mast cells (BMMC),
we have previously demonstrated the synergic action of
co-stimulation of FcεR1 and TLR in the production of
inflammatory cytokines [18].
The endotoxin tolerance phenomenon was described
more than 60 years ago [19], and it is characterized by
hyporesponsiveness to endotoxin exposure, induced by
prior exposure. Cross-tolerance, which is defined by tol-
erance of a different stimulus induced by endotoxin, was
described later. In the context of TLR signaling, the tol-
erance phenomenon can be used as a tool for identifica-
tion of signaling molecules that can attenuate the
inflammatory response, revealing potential participants
in immunomodulation. Mast cells are some of the first
cells to have contact with invading pathogens; when
activated, they release immunoregulatory cytokines that
organize the inflammatory response. The release of
TNFa and the recruitment of circulating leukocytes are
essential elements of the immune response that are
attributed to mast cells, and characteristically, mast cells
are the only type of cell that can store pre-formed
TNFa and release it when activated [20]. Few studies
have addressed endotoxin tolerance in mast cells, likely
due to the fact that its primary role in response to infec-
tion has been defined so recently. In other cell types,
where endotoxin tolerance have been more thoroughly
evaluated, the proteins suppressors of cytokine signaling
(SOCS) are involved in tolerance phenomena as negative
regulators of the pro-inflammatory response, via the
TLR4-NFB pathway [21].
We tested the hypothesis that mast cells display the
phenomenon of direct tolerance to endotoxins after
prestimulation of BMMC with LPS, and that this could
induce cross-tolerance for stimulation with FcεR1 and
TLR2 agonists. The release of TNFa and IL-6 was mea-
sured, and the same experiment was conducted in
BMMC obtained from TLR4
-/- knock-out (KO) mice to
determine the role of TLR4 in the induction of cross-
tolerance and in the potentiation of this response by co-
stimulation. Additionally, we evaluated the effects of
LPS prestimulation on phosphorylation of the mitogen-
activated protein kinase, p38, and the transcription fac-
tor NFB, as well as the expression of the SOCS-1 and




Reagents were obtained from the following sources: cul-
ture medium and reagents from Invitrogen/GIBCO
(Carlsbad, CA); recombinant mouse IL-3 from Pepro
Tech (Rocky Hill, NJ); IgE monoclonal anti-DNP anti-
body and its antigen, dinitrophenylated human serum
albumin (DNP-HSA), and highly purified lipopolysac-
charide (LPS, Escherichia coli 055:B5) from Sigma (St.
Louis, MO); Pam3Cys-Ser-(Lys)4 3HCl (P3C) from
EMC Microcollections GmbH (Tuebingen, Germany);
and polyclonal antibodies that detect phospho-p38
MAPkinase (Thr180/Tyr182), phospho-NFB (Ser536),
and the proteins themselves from Cell Signaling Tech-
nology (Danvers, MA).
Mast cell culture
Bone-marrow derived mast cells (BMMC) were culti-
vated in suspension in 75 cubic milliliter flasks (300,000
cell/ml) in RPMI-1640 supplemented with 5% fetal
bovine serum, 30 ng/ml of IL-3, 2 mM glutamine, 100
μM non-essential amino acids, 10 μM 2-mercaptoetha-
nol, and 1 mM sodium pyruvate. The MC/9 mast cell
line was cultured in the same culture medium without
IL-3. BMMC were obtained from wild-type (C57BL/6)
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-/- KO mice, under approval of the Ethics in
Animal Experimentation Committee [Comitê de Ética
em Experimentação Animal] of the Federal University of
Minas Gerais (CETEA-UFMG), using previously
described procedures [22], and the cells were cultivated
in a CO2 incubator at 37 degrees Celsius. BMMC were
utilized in experiments after 4 weeks in culture and
showed 99% mast cells when stained with toluidine blue.
Experimental protocols
BMMC were sensitized to DNP-HSA (antigen) with 100
ng/ml DNP-IgE and were pretreated with LPS (10 ng/
ml or LPS 100 ng/ml) for 18 hours prior to stimulation.
After 18 hours, cells were washed 3 times with cell cul-
ture medium, resuspended in complete medium and sti-
mulation was performed with antigen (20 ng/ml), LPS
(1 μg/ml), or P3C (1 μg/ml) alone or in combinations
(antigen+LPS or antigen+P3C) for 24 hours for analyz-
ing production of cytokines or 30 min for measuring
degranulation. For signaling studies, BMMC were
washed 3 times with HEPES buffer and stimulated in
the same buffer for 30 minutes with antigen (20 ng/ml),
LPS (1 μg/ml), or a combination of antigen+LPS.
Assay for cytokine measurement
TNFa and IL-6 were measured in the supernatant after
24 hours of stimulation using the enzyme-linked immu-
nosorbent assay (ELISA) method (BioSource kits,
Camarillo, CA).
Measurement of degranulation
For these measurements, cultures were washed and the
medium was substituted with HEPES-buffered saline
medium before stimulation. Degranulation was deter-
mined by the measurement of b-hexosaminidase marker
release by a colorimetric assay in which the release of
p-nitro phenol (coming from p-nitro phenyl-N-acetyl-b-
D-glucosaminide) is measured. Values are expressed as
the percentage of b-hexosaminidase that is released into
the medium.
Immunoblotting
Cells were lysed in a protease/phosphatase-inhibiting
buffer by the addition of 100 μl of this solution to the
cell suspension. This buffer consisted of Complete Pro-
tease Inhibitor Cocktail (Roche Molecular Biochemicals,
Indianapolis, IN), Sigma protease inhibitor cocktail
(Sigma, St Louis, MO), 3-4 dichloroisocoumarin (Roche
Molecular Biochemicals), and benzamidine, as well as
the phosphatase inhibitors sodium orthovanadate,
sodium pyrophosphate, and sodium fluoride (Sigma).
Samples were boiled for 4 minutes, and any existing
debris was removed by centrifugation at 14,000 rpm
for 5 minutes prior to loading the gels. Proteins were
separated by NuPAGE BisTris gels (Invitrogen) and
then transferred to nitrocellulose membranes for
immunoblotting with the primary antibodies indicated.
Visualization was by chemiluminescence, and quantifi-
cation was by densitometry (Kodak Image Station
4000R).
Statistical analysis
The results are provided as mean ± SEM and were ana-
lyzed using the Student t-test with the confidence inter-
val established at 95%. Values were considered
significant if p < 0.05. Data were stored in the Graphpad
Prism 4 statistical program.
Results
Mast cells express endotoxin tolerance not related to the
reduction of toll-like receptor-4 expression
Pretreatment with 100 ng/ml of LPS for 18 hours did
not affect expression of TLR4 in mast cells (Figure 1A).
However, mast cells pretreated with LPS (100 ng/ml)
showed lower production of TNFa upon a second chal-
lenge with LPS (1 μg/ml) compared with cells that not
receive prestimulation (p < 0.05) (Figure 1B).
LPS acts in synergy with antigens through TLR4 signaling
to augment production of cytokines; this potentiation is
reduced by preconditioning with LPS
Similar to the results seen with the MC/9 cell line, pri-
mary BMMC pretreated with LPS (100 ng/ml) showed
lower production of TNFa upon a second challenge
with LPS (1 μg/ml), (p = 0.01). Prestimulation with LPS
(10 ng/ml) was non-significant (p = 0.18) (Figure 2A,
WT). As for IL-6, the same was observed with lower
production upon prestimulation with LPS 100 ng/ml (p
= 0.01) and non-significant with 10 ng/ml (p = 0.17)
(Figure 2B, WT). In comparison with BMMC that did
not receive prestimulation, cells prestimulated with LPS
(100 ng/ml) displayed significantly reduced production
of TNFa and IL-6 upon a second challenge with LPS (1
μg/ml). These results illustrate that prior exposure to
endotoxins induces a significant reduction in the pro-
duction of these proinflammatory cytokines upon a sec-
ond stimulation with LPS (Figures 2A and 2B, WT). In
BMMC from TLR4 knockout mice, we did not detect
production of TNFa or IL-6 in response to a second
challenge with LPS, in cells that were either pretreated
or not treated with LPS (Figure 2A and 2B, TLR4 KO).
To test the hypothesis that a common pathway may
modulate responses to stimulation of the TLR4 and
FcεR1 receptors, BMMC were incubated with DNP-IgE
(50 ng/ml), prestimulated with LPS (10 ng/ml or 100
ng/ml) for 18 hours, and then stimulated with antigen
(20 ng/ml). Prestimulation with 10 ng/ml LPS (p =
0.057) and 100 ng/ml LPS (p = 0.17) did not reduce
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with antigen (Figure 2C, WT). As for IL-6, there was no
reduction with prestimulation with LPS 10 ng/ml (p =
0.1) and 100 ng/ml (p = 0.1) (Figure 2D, WT). The lack
of TLR4 did not affect the production of cytokines in
response to antigen (Figures 2C and 2D, TLR4 KO).
As we have previously demonstrated [18], simulta-
neous stimulation of the FcεR1 and TLR4 receptors
results in greater production of cytokines (TNFa and
IL-6) when compared to the individual stimulation of
each. In support of the common pathway hypothesis, we
demonstrate two new observations in this sequence of
Figure 1 Effect of LPS prestimulation on expression of TLR4 and on TNFa production. The MC/9 mast cell line was prestimulated with LPS
(10 and 100 ng/ml) and the expression of TLR4 (A) and the production of TNFa after a second challenge with LPS (1 μg/ml) (B) were
determined by immunoblotting and ELISA, respectively. The production of TNFa was significantly reduced in a dose-dependent manner after
prestimulation with LPS 100 ng/ml (* p < 0.01). However, this reduction was not mediated by a reduction in TLR4 expression, as shown. Values
are mean and SEM from 3 independent experiments.
Figure 2 Effect of LPS prestimulation on cytokine production after a second challenge with LPS, antigen, or a combination of both.
Reduction of TNFa (A) and IL-6 (B) production after stimulation with 1 μg/ml LPS in BMMC prestimulated with 10 ng/ml LPS (p = 0.18) and 100
ng/ml LPS (p = 0.01). No significant reduction of TNFa (C) or IL-6 (D) production was observed after stimulation with 20 ng/ml Ag in cells
prestimulated with 10 ng/ml LPS (p = 0.057) and 100 ng/ml LPS (p = 0.17). Attenuation of potentiation of TNFa (E) and IL-6 (F) production by
simultaneous stimulation with 20 ng/ml Ag and 1 μg/ml LPS when BMMC were prestimulated with 10 ng/ml LPS (p = 0.16) and 100 ng/ml LPS
(p = 0.01). The TLR4 KO BMMC graphs (A-F) demonstrate that potentiation and attenuation with the FCεR1 agonist and LPS is mediated by TLR4
because there is no significant difference between the non-prestimulated and prestimulated groups. Of note, the synergy with the combination
of LPS+Ag for TNFa (E) and for IL-6 (F) is no longer observed in TLR4 KO BMMC. Values are mean and SEM from 3 independent experiments.
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TNFa (p = 0.01) (Figure 2E) and IL-6 (p = 0.03) (Figure
2F) production between LPS and antigen after precondi-
tioning with LPS (100 ng/ml). Second, this synergism is
dependent on TLR4, as will be demonstrated further on.
Therefore, prestimulation with LPS (100 ng/ml) results
in attenuation of the synergistic effect of co-stimulation
with LPS and antigen.
To determine the role of TLR4, we conducted experi-
ments using the same protocol of prestimulation with
LPS, but stimulated BMMC that do not express TLR4,
which were obtained from TLR4-knockout mice. Neither
tolerance nor a tendency to lower production of proin-
flammatory cytokines were evident when analyzing the
production of TNFa and IL-6 by mast cells obtained from
TLR4 KO mice, whether prestimulation was performed
with LPS at 10 or 100 ng/ml. The synergistic effect of
simultaneous stimulation is thus mediated by TLR4
because this phenomenon was not observed in mast cells
that do not express TLR4 (Figures 2E and 2F, TLR KO).
Preconditioning with LPS did not affect the intensity of
degranulation
For analysis of the effects of prestimulation with LPS (10
ng/ml or 100 ng/ml) on degranulation, we measured the
percentage of b-hexosaminidase released after stimula-
tion with antigen (20 ng/ml), LPS (1 μg/ml) or a combi-
nation of the two. There was no significant change in
the percentage of degranulation in response to any of
the stimuli (data not shown).
Preconditioning with LPS determines cross-tolerance to
the toll-like receptor 2 agonist P3C
After analyzing the influence of TLR4 expression on tol-
erance phenomena in mast cells, we tried to determine
a possible common pathway linking TLR4 and TLR2
responses in endotoxin tolerance. BMMC were presti-
mulated with LPS (100 ng/ml) for 18 hours. After 18
hours, the cells were stimulated with antigen (20 ng/ml),
P3C (1 μg/ml), or a combination of both for 24 hours
for analysis of the production of cytokines. Reduction of
TNFa and IL-6 production after stimulation with P3C
alone (TNFa p = 0.047; IL-6 p = 0.029) or with the
combination of antigen + P3C (TNFa p = 0.012; IL-6
p = 0.004) was observed, but this reduction was not
seen with antigen alone (Figure 3A and 3B).
Prestimulation with LPS leads to an increase in SOCS
expression and in attenuation of phosphorylation of
NFB and p38 MAPkinase after co-stimulation with
antigen and LPS
We also conducted experiments with BMMC that have
been prestimulated with LPS (100 ng/ml) and with non-
prestimulated cells as a control group. After 18 hours,
pre- and non-prestimulated BMMC were stimulated
with 1 μg/ml LPS, 20 ng/ml antigen, or a combination
of both for 30 min. NFBp h o s p h o r y l a t i o nw a s
increased by co-stimulation with antigen and LPS, and
this synergistic effect was reduced by prestimulation
with LPS. After prestimulation with LPS, p38 phosphor-
ylation was also reduced when stimulated with the com-
bination of antigen and LPS (Figure 4A). Prestimulation
with LPS alone resulted in increased expression of
SOCS-1 and -3 in MC/9 cells and increased SOCS-3 in
BMMC cells (Figure 4B). We could not detect expres-
sion of SOCS-1 in BMMC cells.
Discussion
With the increased understanding of the immune
response-regulating mechanisms introduced during the
Figure 3 Effect of LPS prestimulation on cytokine production after a second challenge with antigen, a TLR2 agonist (P3C), or a
combination of both. BMMC were prestimulated with LPS (100 ng/ml) for 18 hours. Next, the cells were stimulated with 20 ng/ml Ag, 1 μg/ml
P3C, or a combination of both for 24 hours for analysis of the production of cytokines. Reduction of TNFa (A) and IL-6 (B) production was seen
after stimulation with P3C alone (* TNFa p = 0.047; * IL-6 p = 0.029) and in combination with Ag + P3C (* TNFa p = 0.012; * IL-6 p = 0.004), but
not with Ag alone (p > 0.05), suggesting a cross-tolerance effect linking TLR2 and TLR4 agonists. Values are mean and SEM from 3 independent
experiments.
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toxins have been seen as a tool to identify mediators
and opportunities in modulation of the inflammatory
response, particularly in sepsis [23]. Our results eluci-
date the phenomenon of direct endotoxin tolerance
mediated by TLR4-NFB pathway and cross-tolerance
of TLR2 agonists in mast cells. Furthermore, we show
synergism between TLR4 and FcεR1 agonists and
attenuation of this response after prestimulation with
LPS. These findings may result at least in part from a
reduction in the phosphorylation of the mitogen-acti-
vated protein kinase, p38, and the transcription factor
NFB, as well as the increase in expression of SOCS-1
and -3 in mast cells.
Membranes of mast cells express Toll-like receptors
that, under stimulation by components of pathogens,
lead these cells to release cytokines, particularly TNFa
and other effector molecules. These cytokines then con-
trol the behavior of other cells, promoting inflammation
and afflux to the infection site [24]. The reprogramming
induced by LPS in mast cells that we have shown here
offers the possibility of evaluating the mechanism of
modulation of the inflammatory response at its roots,
both in response to first contact with the pathogen and
at the level of consequent signaling events. We show
that this reprogramming is not determined by reduction
of TLR4 expression but is mediated by TLR4-NFBs i g -
naling pathway. Reports of the possibility that negative
regulation of the immune response might be mediated
by TLR [25] may be extrapolated to address mast cells.
The synergistic interaction between TLR and FcεR1
receptors was demonstrated by our prior results [18].
The results herein confirmed this synergy and added
information regarding interaction between these recep-
tors, showing the attenuation of synergy by pre-condi-
tioning through TLR4 stimulation with LPS. We also
show the fundamental role of TLR4 in potentiation after
co-stimulation, which is absent in BMMC from TLR4
KO mice. The functional correspondence to human
mast cells with respect to TLR4 and FcεR1 responses
was demonstrated in terms of immune response modu-
lation, including the analysis of genetic expression [26].
Regarding sepsis, common genetic foundations define
the connecting link between the risk of sepsis with
acute pulmonary injury and allergic phenomena such as
asthma [14]. Inflammatory response-regulating mechan-
isms associated with the tolerance phenomenon identi-
fied in this context can possibly be common to an
infectious or allergic response.
Of note is the identification of a cross-tolerance effect
linking TLR4 and TLR2 agonists, which is mediated by
a factor that can influence the transduction mechanisms
of both receptors in mast cells. This suggests a common
signaling pathway or protein that can be a target of
immunomodulation of these receptors. As these recep-
tors are responsible for recognizing components of
Figure 4 Effects of LPS prestimulation on SOCS expression and on phosphorylation of NFB-p65 and p38 after a second challenge
with antigen, LPS, or a combination of both. BMMC were prestimulated with 10 ng/ml LPS or 100 ng/ml LPS for 18 hours. Next, the cells
were stimulated with 20 ng/ml antigen, 1 μg/ml LPS, or a combination of both for 30 min. Figure 4A: NFB-p65 phosphorylation was increased
by co-stimulation with antigen + LPS and this synergistic effect was reduced by prestimulation with LPS, probably corresponding to the
reduction in TNFa and IL-6 production. Under prestimulation, p38 phosphorylation was also reduced when stimulated with the combination of
Ag and LPS. Figure 4B: Prestimulation with LPS by itself resulted in increased expression of SOCS-1 and -3 in MC/9 and SOCS-3 in BMMC cells.
The blots shown were typical results from three experiments. For Figure 4B, images were cropped to allow direct visual comparison from non-
stimulated and stimulated cells from the same gel. Fold induction is the mean of three individual experiments from two BMMC cultures.
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teria, they have become a major target to blunt the pro-
inflammatory response in sepsis. The phenomena of
cross-tolerance has been previously described [27], and
our observations regarding mast cells are new.
We showed attenuation of phosphorylation induced by
reprogramming of mast cells after prestimulation with
LPS, particularly in the TLR4-NFB pathway (probably
corresponding to the reduction in TNFa and IL-6 pro-
duction observed in our experiments). These results are
vital data in the search for mediators that may be used
in an attempt to obtain a more balanced inflammatory
response. Several negative regulators have been
described as being involved in the endotoxin tolerance
process, such as SH2-containing inositol phosphatase
(SHIP) [28]. BMMC from SHIP knockout mice do not
display endotoxin tolerance, probably acting in concert
with IRAK-M and SOCS-1 to downregulate the TLR
signaling pathway. In SHIP
+/+ cells LPS tolerance is
associated with inhibition of NF-B activation, one of
the principal endpoint of LPS signal transduction [28].
In a recent report, SOCS-1 and -3 were described as
suppressor factors involved in a coordinated negative
regulation of innate and adaptive immune responses in
macrophages, dendritic cells and T-lymphocytes [29]. In
our experiments, we show that increases in expression
of SOCS-1 and -3 were associated with tolerance and
cross-tolerance in mast cells. SOCS mediates a negative
feedback mechanism in LPS induced TLR4 transduction,
possibly acting downstream in MyD88 dependent path-
way, at IRAK and p50/p65 levels, in order to reduce the
production of proinflammatory cytokines [30]. The
negative regulation at p50/p65 level may be involved in
FcεR1/TLR4 attenuation of the synergistic activation of
these receptors. Moreover, SOCS 3 inhibit ubiquitina-
tion of TRAF6, preventing association and activation of
TAK1 in the TLR pathway [30]. As TRAF6 contributes
to FcεR1 mediated cytokine production in mast cells
[31], this mechanism is potentially relevant in further
studies addressing the interaction between TLR and
FcεR1 receptors. Accordingly, in mast cells, evidence has
accumulated on their immunomodulating properties,
presenting new opportunities to explore these cells in
inflammatory response imbalance processes [32], such
as sepsis or bronchial asthma.
Conclusions
Mast cells express endotoxin tolerance, and our data
demonstrate dependence on TLR4 for this phenomenon
to occur in response to co-stimulation with LPS and
antigen. These facts strengthen the evidence of interac-
tion between inflammatory responses caused by infec-
tion or allergy through TLR4 and FcεR1 receptors.
Moreover, evidence in the literature on the role of mast
cells in innate immunity and the results presented here
regarding cross-tolerance between TLR4 and TLR2
highlight the relevance of these findings with respect to
sepsis. The association of endotoxin tolerance, cross-tol-
erance involving TLR4, TLR2, FcεR1 receptors, and
SOCS expression implicate these proteins as potential
modulators of innate and adaptive responses. In mast
cells, recently defined as coordinators of innate and
adaptive immunity, use of these potential modulators
likely produces a more balanced inflammatory response
in processes in which imbalance determines damage,
such as in sepsis and allergic diseases.
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